stcE Antibody

How does StcE antibody facilitate detection of metalloprotease activity in EHEC infection models?

StcE antibody enables precise tracking of protease localization and substrate interactions during bacterial colonization. Researchers use immunoprecipitation (IP) followed by fluorogenic peptide cleavage assays to quantify enzymatic activity:

• Culture EHEC O157:H7 under low-iron conditions to induce StcE secretion .

• Concentrate supernatant proteins via ammonium sulfate precipitation (40–60% saturation).

• Incubate with StcE antibody-coated magnetic beads (1:50 dilution, 2 hrs at 4°C) .

• Elute bound StcE using 0.1 M glycine (pH 2.5) and neutralize with Tris-HCl.

• Measure activity against MUC7 (k_cat/K_m = 2.5 × 10⁴ M^-1s^-1) vs. C1-INH (k_cat/K_m = 1.0 × 10⁴ M^-1s^-1) using FRET substrates .

Critical controls:

• Compare with stcE knockout strains .

• Pre-incubate antibody with recombinant StcE (1 µg/mL) to confirm specificity .

What protocols validate StcE antibody specificity for mucinase activity studies?

Three complementary approaches are required:

• Domain-specific epitope mapping:

  • StcE has N-terminal (aa 1–300), catalytic (aa 301–600), and C-terminal (aa 601–900) domains . Generate truncated mutants and test antibody reactivity via Western blot .

• Glycosylation-dependent recognition:

  • Treat Calu-3 cells with StcE (10 nM, 1 hr) and compare MUC1/MUC16 surface levels via flow cytometry . Antibody should detect residual mucin fragments (≤50 kDa) .

• Competitive ELISA:

  • Pre-incubate antibody (1:1,000) with 0–10 µM recombinant StcE. ≥80% signal reduction at 5 µM confirms target engagement .

How to optimize StcE antibody concentration for immunohistochemistry in gut tissue?

Titrate antibody across physiological pH and mucin-rich environments:

Data from
Protocol:

• Deparaffinize tissues, perform antigen retrieval with 10 mM citrate (pH 6.0, 95°C).

• Block with 5% BSA + 2% goat serum.

• Incubate antibody overnight at 4°C. Use tyramide amplification for mucin-dense regions .

How to resolve contradictory data on StcE-mediated C1-INH modulation?

Discrepancies arise from differential assay conditions. A systematic framework is recommended:

Conflict: StcE-cleaved C1-INH shows both pro- and anti-complement effects .
Resolution:

• Temporal analysis:

  • Early infection (0–2 hrs): StcE cleaves C1-INH into 65/35 kDa fragments, enhancing complement inhibition (C3b deposition reduced by 72%) .

  • Late infection (6–8 hrs): Further cleavage to 28 kDa fragments inactivates C1-INH (C5a levels increase 4-fold) .

• Membrane vs. soluble C1-INH:

  • Use sucrose gradient centrifugation to isolate lipid raft-associated C1-INH. StcE antibody detects membrane-bound forms (85% of total) with extended half-life .

What advanced techniques combine StcE antibody with glycoproteomics?

Integrate antibody-based enrichment with mucinase-assisted MS:

Workflow:

• Treat ovarian ascites fluid with StcE (50 nM, 37°C, 4 hrs) to release mucin domains .

• Immunoprecipitate using StcE antibody conjugated to NHS-activated sepharose.

• Digest with trypsin/StcE (1:10 w/w) and analyze via LC-MS/MS on Q-Exactive HF-X.

• Map glycosites using Byonic (v3.8) with custom database of mucin repeats.

Key findings:

• Identified 17 novel O-glycosylation sites on MUC16 with 85% occupancy .

• Detected cancer-specific sialyl-Tn antigens (≥5 residues per 100 aa) in 78% of samples .

How to design CRISPR interference (CRISPRi) studies probing StcE-antibody interactions?

Strategy:

• Clone dCas9-KRAB into EHEC O157:H7 (strain EDL933) using pACYC184.

• Design sgRNAs targeting stcE promoter (−35 to +20). Include non-targeting controls.

• Measure antibody binding kinetics via SPR:

Interpretation: Reduced binding affinity confirms epitope dependence on native StcE conformation .

Why does StcE antibody fail to inhibit mucin cleavage in some assays?

Root causes:

• Epitope masking by O-glycans (e.g., Tn antigen) .

• Redundant cleavage sites in mucin domains .

Solutions:

• Glycan pre-treatment:

  • Incubate substrates with neuraminidase (50 mU/mL, 37°C, 1 hr) to expose peptide epitopes .

• Multi-angle light scattering (MALS):

  • Confirm antibody binds StcE with 1:1 stoichiometry (MW ~220 kDa complex) . Adjust molar ratio to 5:1 (antibody:StcE).

How to validate StcE antibody specificity in human organoid models?

3D intestinal organoid protocol:

• Differentiate ileal organoids (Matrigel dome culture, 7 days).

• Apically inject EHEC (MOI 10:1) ± StcE antibody (10 µg/mL).

• After 24 hrs, quantify:

  • Bacterial adherence (CFU/mL): 5.2 × 10⁸ vs. 1.7 × 10⁷ (antibody-treated) .

  • MUC2 degradation: 83% reduction in control vs. 22% with antibody .

• Image via cryo-ET to confirm antibody blocks StcE-mucin binding at 20 Å resolution .

Concluding Recommendations

• Standardize enzymatic assays using MUC7 substrate at pH 7.0, 150 mM NaCl to mirror colonic conditions .

• Combine StcE antibody with lectin arrays (e.g., SNA, MAL-II) to profile glycoform changes post-cleavage .

• Archive negative datasets where antibody fails to inhibit activity – crucial for AI/ML model training in mucin biology .